Overweight with confirmation-gated execution: Scale-in tranches on momentum stabilization, hard stop $203.50
Maintain Overweight conviction with disciplined execution that defers initial deployment to confirmation gates. The structural case is verified by $289B backlog, $22.67B deferred revenue (+18% YoY), TTM FCF $9.88B, and sole-source franchises; however, aggressive deployment at $212 with deteriorating momentum (MACD -2.22, RSI 49, price below 10-EMA) risks underperformance as seen in 8/24 Overweight at $208.50 (+0.2% alpha) vs. Hold-with-conditional-triggers at -0.6% alpha. The split-deployment framework captures structural upside if momentum confirms, exits before the bear case if it doesn't, and avoids both eagerness and entry paralysis. Near-term price target $225; extended target $230-240.
| Position | Action |
|---|---|
| Price flush to $205-207 with MACD histogram turning less negative | Deploy Tranche A (partial position) |
| 10-EMA reclaim above $214.50 with RSI >50 and MACD flattening | Deploy Tranche B (additional position) |
| Total portfolio weight | Cap at 1-3% combined deployment |
| Price below $203.50 | Hard stop — invalidates pullback-within-uptrend thesis |
RTX is being given away at the bottom of a healthy pullback inside a roaring secular uptrend — a $285B aerospace & defense prime with record backlog, accelerating free cash flow, and structural margin recovery trading at a 7% pullback from its 52-week high.
| Indicator | Value | Signal |
|---|---|---|
| close | 212.08 | neutral |
| 10-EMA | 214.11 | bearish |
| 50-SMA | 204.93 | bullish |
| 200-SMA | 190.89 | bullish |
| RSI (14) | 49.07 | neutral |
| MACD | 1.60 | bearish |
| MACD Signal | 3.82 | bearish |
| MACD Histogram | -2.22 | bearish |
| Bollinger Upper Band | 228.67 | neutral |
| Bollinger Middle Band | 217.93 | neutral |
| Bollinger Lower Band | 207.18 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: 10-EMA reclaim above $214.50 with RSI >50 and MACD flattening
Then: Scale in Tranche B
$289B backlog with $22.9B in Tomahawk production orders represents contracted, not speculative, revenue; deferred revenue of $22.67B up 18% YoY confirms cash already collected
↩ rebuts: “Bear objection that backlog isn't the same as revenue and companies pad backlogs”
EV: +13.9% (from $210 to $228 upper Bollinger Band target) · concedes: Short-term technical setup is bearish (price below 10-EMA, MACD bearish crossover); Forward P/E of 27x is not cheap; Additional GTF powder-metal findings remain a medium-probability risk; Tariff/supply chain shock risk is low-medium; The bear's only legitimate foothold is the short-term technical damage
RTX is a textbook bull trap at the end of a 16% vertical rally—trading at the highest multiple in its defense peer group (27x forward P/E), with a goodwill-laden balance sheet, deteriorating short-term momentum, and a GTF remediation timeline that has been wrong every time management has given one. Wonderful company, wrong price.
· concedes: RTX is a high-quality aerospace & defense franchise with structural demand tailwinds; GTF recovery story is real (eventually, timing uncertain); Exceptional backlog exists
→ vs conservative: MACD bearish crossover at -222 and RSI at 49 represent normal consolidation, not breakdown; stock holding above 50-day SMA and 11% above 200-day SMA
→ vs conservative: Waiting for RSI 40 and Bollinger Band tag at $205-207 is 'performance anxiety masquerading as precision' and risks missing re-rating event
→ vs conservative: 1-3% max position size treating RTX like speculative biotech when it's actually a AAA-rated industrial compounder with government-backed revenue
→ vs neutral: 27x forward P/E premium justified by unique combination of defense prime status AND commercial aerospace cycle inflection that LMT, NOC, and GD cannot match
→ vs conservative: Scale-in sizing of 1.5% with 25-33% in reserve is a 'rounding error' for a name with 29% forward EPS growth and zero point two nine beta
| bullish |
| ATR (14) | 4.47 | neutral |
Support: 207.18 · 204.93 · 200 | Resistance: 217.93 · 225.49 · 228.67
RTX is in a short-term pullback within a longer-term bullish trend. The stock closed at $212.08 on 2026-08-27, sitting below the 10-EMA (214.11) with a bearish MACD crossover (line at 1.60 crossing below signal at 3.82; histogram at –2.22), and pressing against the lower Bollinger Band at $207.18. However, the medium and long-term trends remain intact: price is 3.5% above the 50-SMA (204.93) and 11.1% above the 200-SMA (190.89). RSI at 49.07 is neutral with room to fall further before reaching oversold territory. The ATR of 4.47 indicates elevated daily volatility warranting wider stop distances. Key resistance sits at 217.93 (BB middle), 225.49 (swing high), and 228.67 (BB upper), while key support is at 207.18 (BB lower), 204.93 (50-SMA), and 200.00 (psychological). The overall tactical bias is neutral-to-defensive, with a HOLD recommendation: existing holders should hold through the pullback while new entries are not advised at current levels.
Market Cap
$285.8 B
P/E (TTM)
37.3x
Forward P/E
27.0x
PEG
2.61
P/B
4.31x
Dividend Yield
1.38%
Beta
0.29
Revenue (TTM)
$93.5 B
EBITDA
$15.9 B
Net Income
$7.74 B
EPS (TTM)
$5.68
EPS (Forward)
$7.86
ROE
12.3%
ROA
4.2%
Revenue 4Y CAGR
~8.6%
EPS Recovery (2023 to 2025)
+122%
Forward EPS Growth Implied
+38%
Total Assets
$174.0 B
Total Debt
$38.9 B
Net Debt
$29.1 B
D/E Ratio
~0.52x
Current Ratio
1.01
Deferred Revenue
$22.7 B
Goodwill & Intangibles
$84.0 B
Tangible Book Value
-$17.6 B
FCF (2025)
$7.45 B
FCF (TTM)
$9.88 B
Capex (2025)
$2.63 B
Dividends (2025)
$3.57 B
Buybacks (2025)
$0.05 B
50-Day MA
$204.96
200-Day MA
$192.08
52-Week Range
$150.61 – $226.88
Q2'26 Revenue
$24.71 B
Q2'26 EPS
$1.57
Q2'26 FCF
$2.82 B
Gross Margin (TTM)
~20.4%
Operating Margin
12.7%
Net Margin
8.3%
Strengths
Concerns
RTX Corporation presents a classic mid-cycle recovery profile in a structurally growing aerospace and defense industry. The fundamental case rests on three legs: (1) earnings recovery from the GTF trough — 2023 EPS of $2.23 to 2025's $4.96 to consensus 2026 ~$7.50 trajectory is well-supported by quarterly data; (2) exceptional backlog visibility with $22.7B in deferred revenue and growing defense demand providing a multi-year revenue floor; and (3) inflecting free cash flow with TTM FCF of ~$10B supporting both continued deleveraging and likely return to buybacks in 2027 as a potential catalyst. The stock trades above both its 50-day ($204.96) and 200-day ($192.08) moving averages, roughly 10% above the 200-day MA and 6.5% below its 52-week high of $226.88, representing a constructive uptrend with healthy consolidation. Forward P/E of 27x is not cheap — the premium valuation is justified only if forward EPS estimates hold; any GTF re-escalation or defense budget pullback would compress multiples quickly. Risk/reward favors patient accumulation on weakness toward the 50-day MA (~$205).
Macro: Fed policy: 88% probability of zero Fed cuts in 2026 (rising +2.2pp in the last week). Recession: 8% probability of US recession by end-2026 (light-volume market, +1.0pp last week). FRED macro indicators (CPI, Fed funds, 10Y yield, core PCE): data unavailable — API key unconfigured.